{"filing":{"accession_number":"0001437749-26-018819","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"mbrx20260529_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926018819/mbrx20260529_8k.htm"},"events":[{"id":8189,"run_id":7182,"accession_number":"0001437749-26-018819","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces new clinical data for Moleculin's lead drug candidate Annamycin presented at ASCO, highlighting a \"differentiated cardiac safety profile.\" This is material clinical trial progress for a biotech company with a lead candidate in development, as it addresses a critical safety concern that could influence investor assessment of the drug's commercial viability and regulatory pathway. However, it does not fit neatly into earnings_release (no financial results), material_litigation, or other more specific categories, making other_material the most appropriate classification.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2814,"accession_number":"0001437749-26-018819","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces new clinical data for Moleculin's lead drug candidate Annamycin presented at ASCO, highlighting a \"differentiated cardiac safety profile.\" This is material clinical trial progress for a biotech company with a lead candidate in development, as it addresses a critical safety concern that could influence investor assessment of the drug's commercial viability and regulatory pathway. However, it does not fit neatly into earnings_release (no financial results), material_litigation, or other more specific categories, making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:35:09.676350+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2814,"accession_number":"0001437749-26-018819","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces new clinical data for Moleculin's lead drug candidate Annamycin presented at ASCO, highlighting a \"differentiated cardiac safety profile.\" This is material clinical trial progress for a biotech company with a lead candidate in development, as it addresses a critical safety concern that could influence investor assessment of the drug's commercial viability and regulatory pathway. However, it does not fit neatly into earnings_release (no financial results), material_litigation, or other more specific categories, making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:35:09.676350+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-05-29"}]}